scholarly journals Therapy of high malignant Non-Hodgkin-Lymphoma (NHL) stage I, of low malignant NHL stages I and II, and of centroblastic-centrocytic lymphoma stages I–III

1986 ◽  
Vol 111 (S1) ◽  
pp. S5-S5
Author(s):  
H. Sack ◽  
St. L. Roth
Keyword(s):  
Hodgkin Lymphoma ◽  
Stage I ◽  
Non Hodgkin Lymphoma

Alternating chemotherapy and radiotherapy combination for bulky stage I and II intermediate and high grade non-Hodgkin lymphoma: an update

1991 ◽  
Vol 20 (1) ◽  
pp. 30-37 ◽  
Author(s):  
J.M. Cosset ◽  
M. Henry-Amar ◽  
T. Vuong ◽  
P. Carde ◽  
T. Girinsky ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Stage I ◽  
High Grade ◽  
Non Hodgkin Lymphoma ◽  
Alternating Chemotherapy

scholarly journals Erratum to: Radiotherapy in stage I-III follicular non-Hodgkin lymphoma. Retrospective analysis of a series of 50 patients

2012 ◽  
Vol 189 (2) ◽  
pp. 168-169 ◽  
Author(s):  
K. Fakhrian ◽  
S. Klemm ◽  
U. Keller ◽  
C. Bayer ◽  
W. Riedl ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Hodgkin Lymphoma ◽  
Stage I ◽  
Non Hodgkin Lymphoma

Prognostic Factors in Non-Hodgkin Lymphoma Stage I Treated with Radiotherapy

1989 ◽  
Vol 28 (1) ◽  
pp. 45-50 ◽  
Author(s):  
H. Hagberg ◽  
U. Pettersson ◽  
B. Glimelius ◽  
C. Sundström
Keyword(s):  
Prognostic Factors ◽  
Hodgkin Lymphoma ◽  
Stage I ◽  
Non Hodgkin Lymphoma

Radiotherapy in stage I–III follicular non-Hodgkin lymphoma

2012 ◽  
Vol 188 (6) ◽  
pp. 464-471 ◽  
Author(s):  
K. Fakhrian ◽  
S. Klemm ◽  
U. Keller ◽  
C. Bayer ◽  
W. Riedl ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Stage I ◽  
Non Hodgkin Lymphoma

scholarly journals Stage I Non‐Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement

2018 ◽  
Vol 185 (2) ◽  
pp. 334-338 ◽  
Author(s):  
Dai Chihara ◽  
Yasuhiro Oki ◽  
Michelle A. Fanale ◽  
Jason R. Westin ◽  
Loretta J. Nastoupil ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Survival Outcome ◽  
Stage I ◽  
Extranodal Site ◽  
Non Hodgkin Lymphoma

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

2019 ◽  
Vol 98 (5) ◽  
pp. 1169-1176 ◽  
Author(s):  
Dai Chihara ◽  
Yasuhiro Oki ◽  
Michelle A. Fanale ◽  
Jason R. Westin ◽  
Loretta J. Nastoupil ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Stage I ◽  
Disease Specific Survival ◽  
Non Hodgkin Lymphoma ◽  
Disease Specific

scholarly journals Early cytological diagnosis of extranodal stage I, primary thyroid Non-Hodgkin lymphoma in elderly patients. Report of two cases and review of the literature

BMC Surgery ◽  
2013 ◽  
Vol 13 (Suppl 2) ◽  
pp. S49 ◽  
Author(s):  
Elena Vigliar ◽  
Alessia Caleo ◽  
Mario Vitale ◽  
Vincenzo Di Crescenzo ◽  
Alfredo Garzi ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Hodgkin Lymphoma ◽  
Stage I ◽  
Cytological Diagnosis ◽  
Review Of The Literature ◽  
Non Hodgkin Lymphoma

Non-Hodgkin lymphoma in children: Is 1 g/m2 methotrexate as effective as 5 g/m2 in advanced-stage nonlymphoblastic non-Hodgkin lymphoma?

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 10043-10043
Author(s):  
Rejin Kebudi ◽  
Bulent Zulfikar ◽  
F Betul Cakır ◽  
Omer Gorgun ◽  
Inci Ayan ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Demographic Data ◽  
Survival Rates ◽  
Stage Iv ◽  
Large Cell ◽  
Stage I ◽  
Advanced Stage ◽  
Non Hodgkin Lymphoma ◽  
Time Period ◽  
Stage Iv Disease

10043 Background: Survival rates in non-Hodgkin lymphoma (NHL) have increased significantly in the last decades. This study aims to assess the demographic data and treatment results of children with nonlymphoblastic NHL treated in a single institution. Methods: 106 children (74 male, 32 female), treated in Istanbul University, Oncology Institute, between 9/1989-12/2012 were evaluated retrospectively. Nonlymphoblastic NHL received COMP until 1991. After then, all received BFM protocols. They received BFM 90 protocol with 5 g/m2 methotrexate (MTX) until 1995 and modified BFM protocol with 1 g/m2 MTX thereafter. Results:The median age was 8(2-19) years. Histopathologic subtypes: 81 Burkitt, 25 large cell. The primary location was abdomen in 51, mediastinum 4, head/neck 31, 20 other (bone 8, breast 2, ovaries 2, skin 2, paravertebral 2, other 4). Bone marrow was involved in 10, CNS in 2. 40 patients had stage I+II, 44 stage III, and 22 stage IV disease. 23 patients died, 7 due to toxicity, 2 with second malignancies (AML,GBM). 10 year survival and EFS in the whole group was 76 and 76 % respectively. 10 year survival was 100, 94.3, 71.3 and 50% in stage I, II, III, and IV. In advanced stage nonlymphoblastic NHL patients, 10 year survival was significantly higher in patients receiving BFM regimen with 1 g/m2 MTX, than in ones receiving COMP or BFM protocol with 5 g/m2 MTX (10 year S, 81%, 46.7%, 44.4% respectively). These results were also compared with 47 advanced stage nonlymphoblastic NHL patients treated with 5 g/m2 BFM protocol in another center in the same university in the same time period (5 year S 78 %). Conclusions: Survival rates in the whole group are in parallel with advances attained in the world in NHL. The significantly higher survival rates achieved in patients with advanced stage non-lymphoblastic patients receiving modified BFM (1g/m2MTX) may be due to the decreased toxicity seen in this group and to the advances in supportive care in the last decade. In another major center in the same university that used the same protocol with 5 g/m2 MTX in the same time period, similar survival rates suggest that 1 g/m2 MTX which is cheaper and less toxic is also as effective as 5 gr/m2 in these patients.

Sign in / Sign up

Export Citation Format

Share Document